This research indicates that a small-molecule compound affecting mitochondrial magnesium levels can prevent obesity and related metabolic diseases in mice subjected to a high-fat, high-sugar diet.
A team of researchers at The University of Texas Health Science Center at San Antonio has identified a promising small-molecule drug candidate that has shown potential in preventing obesity and metabolic damage in mice subjected to a long-term high-fat, high-sugar diet, commonly referred to as a Western diet. The study, published on February 27, 2023, in Cell Reports, highlights the role of magnesium transport within mitochondria as a novel target for addressing obesity-related health issues.
The compound, which researchers have named CPACC, was effective in preventing weight gain in mice while also protecting them from liver damage commonly associated with poor dietary habits, including fatty liver disease and tumor formation. This study not only demonstrates the drug’s efficacy but also introduces a new understanding of how magnesium dynamics within cells can influence metabolic health.
Understanding Magnesium’s Role in Metabolism
Magnesium is a crucial mineral for various physiological processes in the body, including the regulation of blood sugar and blood pressure, and it plays a significant role in cellular energy production. It is the fourth most abundant mineral in the human body, surpassed only by calcium, potassium, and sodium. However, the findings from this study suggest that excessive magnesium within mitochondria might inhibit the cell’s ability to metabolize sugars and fats efficiently.
Madesh Muniswamy, PhD, a professor of medicine and the senior author of the study, emphasized the implications of the research: “When we give this drug to the mice for a short time, they start losing weight. They all become slim.” The team observed that in normal mice fed a Western diet, significant weight gain and metabolic disease symptoms developed, whereas mice genetically modified to lack the MRS2 gene, which regulates magnesium entry into mitochondria, remained lean and metabolically healthy.
Impact on Liver Health
The study’s findings regarding liver health were particularly striking. Mice with the MRS2 knockout exhibited minimal liver damage, which typically includes fatty liver changes, fibrosis, and even tumor formation as a consequence of a high-fat diet. In contrast, typical mice displayed significant liver enlargement and other concerning symptoms associated with obesity and metabolic syndrome.
These results underscore the potential of targeting mitochondrial magnesium channels as a therapeutic strategy for obesity and related liver disorders. The researchers noted that altering magnesium transport affected how cells handled citrate, a critical molecule in fat synthesis, thereby reducing fat accumulation in both the liver and body.
Development of CPACC
To further demonstrate the therapeutic potential of their findings, the team developed CPACC, a compound that inhibits magnesium transport through the mitochondrial pathway controlled by MRS2. UT Health San Antonio has filed a patent application for this drug. In experimental trials, CPACC was shown to significantly reduce lipid accumulation in liver cells, enhance mitochondrial respiration, and lower plasma citrate levels. Additionally, mice injected with CPACC every three days over a six-week period experienced limited weight gain and improved liver function markers.
Co-lead author Manigandan Venkatesan, PhD, noted, “Lowering the mitochondrial magnesium mitigated the adverse effects of prolonged dietary stress.” This collaborative effort involved contributions from researchers at the University of Pennsylvania and Cornell University, reinforcing the importance of interdisciplinary approaches in addressing complex health issues.
Future Implications
The findings from this research have significant implications for the treatment of obesity, fatty liver disease, type 2 diabetes, and other cardiometabolic conditions. While the results are promising, the researchers caution that further studies are necessary, particularly those involving human subjects, to refine and ensure the safety of MRS2 modulators for potential clinical use. Muniswamy remarked on the long-term vision of their work: “A drug that can reduce the risk of cardiometabolic diseases such as heart attack and stroke, and also reduce the incidence of liver cancer, which can follow fatty liver disease, will make a huge impact.”
Ongoing Research
Subsequent studies published after the initial CPACC research have continued to explore the relationship between mitochondrial magnesium transport and various health conditions. For instance, a study in Mitochondrion published in 2024 highlighted how reduced mitochondrial magnesium levels can enhance calcium signaling within cells, while a 2026 study in Hypertension linked MRS2 to pulmonary arterial hypertension, indicating broader implications for understanding metabolic dysfunctions.
The ongoing research underscores the necessity of continued exploration into mitochondrial function and magnesium’s role in metabolic health, with the hope of translating these findings into effective treatments for human health challenges related to obesity and metabolic syndrome.
No Comment! Be the first one.